Claims for Patent: 6,015,708

Summary for Patent: 6,015,708

Title:	Gene manipulation and expression using genomic elements
Abstract:	Expression of mammalian target genes is achieved by employing chromosomal target DNA, either native primary cells or YACs in a yeast host, where the YACs include a fragment of a mammalian chromosome, the fragment comprising the target gene. Employing homologous recombination, an amplifiable gene is integrated into the mammalian fragment at a site to allow for amplification. In the same step, or one or more steps, as desired, the mammalian gene and/or the transcriptional system may be modified by in vivo mutagenesis. The resulting construct from homologous recombination may then be transformed into a mammalian expression host and integrated into the host genome, either randomly or by homologous recombination. The amplifiable gene may then be amplified by an appropriate agent providing for multiple copies of the target gene and the expression host grown to provide for high yields of the desired wild-type or modified protein.
Inventor(s):	Sherwin; Stephen (San Francisco, CA), Klapholz; Sue (Stanford, CA), Skoultchi; Arthur (Larchmont, NY)
Assignee:	Cell Genesys, Inc. (Foster City, CA)
Application Number:	08/462,947
Patent Claims:	1. A yeast artificial chromosome comprising mammalian DNA that includes a mammalian target gene, wherein a nucleotide regulatory sequence, heterologous to the mammalian target gene, is in operable association with the mammalian target gene such that the nucleotide regulatory sequence directs expression of the mammalian target gene when the yeast artificial chromosome is present in a mammalian cell. 2. The yeast artificial chromosome of claim 1 in which the yeast artificial chromosome further contains an amplifiable gene operably associated with the mammalian gene. 3. The yeast artificial chromosome of claim 1 or 2 in which the mammalian gene is a human gene. 4. The yeast artificial chromosome of claim 1 or 2 in which the heterologous regulatory sequence is a viral promoter or a promoter/enhancer. 5. The yeast artificial chromosome of claim 4 in which the promoter/enhancer is a cytomegalovirus promoter/enhancer. 6. The yeast artificial chromosome of claim 2 in which the amplifiable gene is dihydrofolate reductase, metallothionein-I, metallothionein-II, adenosine deaminase, ornithine decarboxylase, or glutamine synthetase. 7. The yeast artificial chromosome of claim 1 or 2 in which the mammalian gene further contains a mutation located in an amino acid coding region, an intron, a 5'-untranslated region, or a 3'-untranslated region. 8. A yeast host containing the yeast artificial chromosome of claim 1. 9. A yeast host containing the yeast artificial chromosome of claim 2. 10. A yeast host containing the yeast artificial chromosome of claim 3. 11. A yeast host containing the yeast artificial chromosome of claim 4. 12. A yeast host containing the yeast artificial chromosome of claim 5. 13. A yeast host containing the yeast artificial chromosome of claim 6. 14. A yeast host containing the yeast artificial chromosome of claim 7. 15. A mammalian continuous cell line transformed with the yeast artificial chromosome of claim 1, or progeny of the transformed cell line, that express the mammalian gene controlled by the heterologous nucleotide regulatory sequence. 16. A mammalian continuous cell line transformed with the yeast artificial chromosome of claim 2, or progeny of the transformed cell line, that express the mammalian gene controlled by the heterologous nucleotide regulatory sequence, which mammalian gene is amplified under conditions that amplify the amplifiable gene. 17. The mammalian continuous cell line of claim 15 or 16 in which the mammalian gene is a human gene. 18. The mammalian continuous cell line of claim 15 or 16 in which the heterologous regulatory sequence is a viral promoter or a promoter/enhancer. 19. The mammalian continuous cell line of claim 18 in which the promoter/enhancer is a cytomegalovirus promoter/enhancer. 20. The mammalian continuous cell line of claim 16 in which the amplifiable gene is dihydrofolate reductase, metallothionein-I, metallothionein-II, adenosine deaminase, ornithine decarboxylase, or glutamine synthetase. 21. The mammalian continuous cell line of claim 15 or 16 in which the mammalian gene further contains a mutation located in a amino acid coding region, an intron, a 5'-untranslated region, or a 3'-untranslated region.

Details for Patent 6,015,708

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-01-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-01-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-01-18